Drugs / GSK3389404
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02647281 | Dec 2015 → Jan 2017 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03020745 | Feb 2017 → Jan 2019 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3389404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02647281 ↗ |
| Action | Inhibit | “GSK3389404 is an investigational agent that targets HBV RNA, resulting in reduced viral protein production.” PMID 35714812 ↗ Jun 2022 |
| Route | Subcutaneous | “by subcutaneous injection” NCT02647281 ↗ |